Clinical experience with amikacin, a new aminoglycoside antibiotic by Theron, F. P. & De Kock, M. A.
746 SA MEDIESE TYDSKRIF
TABLE I. PELVIC RADIOGRAPHS OF 727 WHITES RESULTS
21 Mei 1977
Male Female
Age
(yrs)
0-20
21 - 30
31 - 40
41 - 50
51 - 60
61+
Total
Without
phleboliths
30
48
39
27
23
31
198
With
phleboliths
1
14
30
30
31
36
142
Without
phleboliths
45
62
37
19
20
21
204
With
phleboliths
3
8
30
35
48
59
183
Tables I and 1I indicate the frequency of phleboliths
according to race, age and sex. Blacks have far fewer
phleboliths than Whites and the results are meaningful at
the I % level of significance.
Fig. 1 shows the differing rates of increase with age
in the proportion of people with phleboliths. It is possible
that the dip in the graph of the Black group is due to an
increasing incidence in younger, westernized people.
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Clinical Experience with Amikacin, aNew .i\minoglycoside
Antibiotic
F. P. THERON,
SUMMARY
Amikacin, a new semisynthetic aminoglycoside antibiotic,
was administered parenterally to 20 patients suffering
from severe Gram-negative bacterial infections. The anti-
biotic was found to be highly effective in controlling in-
fection. It was well tolerated and no signs of nephro- or
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ototoxicity were observed. The few side-effects which
were seen appeared to be dose-related. The recommended
12-hourly dosage regimen has also proved useful in
medium- to long-term management of refractory pulmo-
nary infections.
S. Afr. med. J., 51, 746 (1977).
Amikacin (BB - K8) is a semisynthetic aminoglycoside anti-
biotic derived from kanamycin. It has pharmacological
properties similar to those of the parent substance, kana·
mycin. Amikacin has an extremely broad spectrum of
antibacterial activity, and is claimed to be more resistant
to aminoglycoside-inactivating enzymes than any amino-
glycoside in current clinical use.' In common with related
aminoglycosides, amikacin might be expected to possess
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10xic properties. particularly in respect of the patient with
impaired renal function. Gentamicin, for example. ha
been shown to produce acute nephrotoxicity ami ototoxi-
city, and to possess neuromuscular blocking potentiaL""
Animal experimentation has uggested that the tendency
to cause toxicity noted in the specific drug under trial
was probably dose-related, occurring consistently in the
dosage range of 30 mgjkg/d.'·' Such levels exceed by a
substantial margin the recommended daily dose (15 mg kg)
of amikacin for clinical use.
The purpose of this study was to evaluate the preclinical
therapeutic claims made for the efficacy of amikacin in
combating Pseudomonas organisms and other Gram-nega-
tiv~ bacteria frequently implicated in drug-resistant micro-
bial infections. particularly of the lungs.
PATIENTS AND METHODS
Patient Selection
All the subjects participating in the trial had given
written informed consent to the administration of amikacin
in the treatment of their disease. It was explained to them
that the wider effects of the drug were unknown, although
the limited clinical trials conducted elsewhere to date had
yielded very few untoward effects. and that the latter had
been similar to those encountered with other drugs in the
aminoglycoside group currently in general use.
There were 20 patients with mixed Gram-negative in-
fections which had. in 25.... of cases. previously been
treated unsuccessfully with other antibiotic drugs. The
seriousness of the patients' illnesses did not permit the
incorporation of double-blind techniques employing alter-
native aminoglycoside drugs in the design of the trial,
and no control could be exercised other than thorough and
objective clinical and laboratory ob ervation.
The age of the patients varied from l-l to 70 year
(average 47.5 years) and there were 14 male and 6 female
ubjects. Fourteen of these patient could be classified as
seriou Iy ill with life-threatening infections. while the re-
mainder had moderately severe infections. The primary
diagnoses are detailed in Table I. and these included a
variety of bronchial. parenchymal and pleural pulmonary
infe tion and a single case of septicaemia proved on blood
culture.
Methods
All patients were individually evaluated by the authors
before undergoing a predetermined set of investigations
prior to the institution of amikacin therapy. This docu-
mentation included the following:
(a) the measurement of height and body mass:
(b) the maintenance of fluid balance charts, with regular
microscopical and biochemical urinalysis:
(c) complete blood cell counts;
(d) liver function tests;
(e) the evaluation of auditory and vestibular function
- after consulting our Ear. Nose and Throat De-
partment. we considered the following tests ade-
quate for our purposes: audiogr-aphy and enquiry
after conversational deafness, vertigo and tinnitus
and examination for nystagmus;
(f) serum creatinine and blood urea determinations;
(g) records of arterial blood pressure, pulse rate and
oral temperature. charted 6-hourly;
(h) daily bacteriological culture of collected sputum.
TABLE I. SUMMARY OF PATIENT DATA
Duration of Amikacin Duration of
Case illness dosage treatment
o. Age Primary diagnosis Causative organism (days) Prior therapy (mg/kg/d) (days) Result
64 Bronchopneumonia Klebsiella pneumoniae 10 Ampicillin 12,0 17 Fair
Penicillin, ampi-
2 63 Bronchopneumonia Gram-negative 5 cillin 12,0 13 Excellent
3 25 Septicaemia Pseudomonas aeruginosa 2 Nil 19,5 8 Excellent
Streptomycin, INH,
4 36 Empyema Proteus mirabilis 30 ethambutol 17,8 21 Excellent
5 45 Lobar pneumonia Klebsiella pneumoniae 14 Nil 15,1 9 Excellent
6 45 Lung abscess Gram-negative 7 Nil 19,6 44 Good
7 55 Bronchopneumonia Klebsiella pneumoniae 10 Nil 14,2 5 Excellent
8 65 Bronchopneumonia Enterobacter 14 Nil 27,0 10 Poor
9 51 Lobar pneumonia Klebsiella pneumoniae 2 Nil 16,6 22 Good
10 18 Bronchopneumonia Klebsiella pneumoniae 7 Nil 24,3 8 Excellent
11 70 Bronchopneumonia Unknown 7 Nil 15,3 8 Excellent
12 14 Bronch'ectasis Pseudomonas aeruginosa 14 Nil 27,3 12 Good
13 60 Lobar pneumonia Klebsiella pneumoniae 2 Nil 19,2 10 Good
14 61 Bronchiectasis Pseudomonas 4 Amoxycillin 20,8 7 Excellent
15 53 Bronchopneumonia Klebsiella pneumoniae 3 Ampicillin 19,2 10 Excellent
16 45 Lobar pneumonia Klebsiella pneumoniae 14 Nil 17,5 10 Excellent
17 48 Bronchiectas is Klebsiella pneumoniae 21 Nil 15,0 7 Excellent
18 25 Bronchopneumonia Klebsiella pneumoniae 10 Nil 22,6 10 Excellent
19 67 Lung abscess Klebsiella pneumoniae 14 Nil 15,1 19 Excellent
20 40 Lobar pneumonia Klebsiella pneumoniae 5 Nil 15,3 9 Excellent
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These investigations were repeated at regular intervals
or continued throughout the period of drug trial therapy,
and were maintained for some days after the cessation of
treatment, subject to the emergence of side-effects ascribed
to the drug. The results of therapy were assessed in terms
of the clinical response, being adjudged excellent, good,
fair or poor, according to such criteria as improvement in
toxic-febrile state. diminished cardiac and respiratory rates,
favourable leucocyte and sedimentation rate response, and.
most important, the persistent absence of the offending
pathogen from the patient's sputum, signifying eradication
of the Gram-negative infection.
RESULTS
A summary of the patient data is provided in Table 1.
The findings in 6 patients deserve further discussion in
view of the opportunistic nature of the infection in a
compromised host situation, presumably unrelated super-
vening clinical events, the emergence of side-effects of the
drug, or failure of antibiotic therapy to prevent irreparable
loss of function.
The clinical and bacteriological response to amikacin in
patient 7 was excellent. He made rapid progress towards
complete recovery, only to succumb unexpectedly to acute
anterolateral myocardial infarction on the fifth day of
therapy.
Patient 12, a 14-year-old girl with mucoviscidosis and
proven secondary amyloidosis and a long history of re-
current pulmonary infection in relation to bronchiectasis,
developed acute bronchitis with marked central cyanosis.
Pseudomonas aeruginosa was cultured from the sputum
and amikacin was commenced as primary antibiotic therapy.
In view of the severity of the infection, and the critical
general condition of the patient, she received a very high
dosage, 27,3 mg/kg/d. The clinical response to the drug
was good and the pathogen was eradicated from the sputum
within 14 days, but the blood platelet count had decreased
from the control value of 340000/,Lt1 to 62000/,Lt1 at this
stage and the drug was discontinued. The thrombocyte
count gradually returned to normal levels within 2 weeks
and the patient's further clinical progress was satisfactory.
The only other untoward effect of the drug noted in
this series occurred in patient 6. He was a 45-year-old
man who received amikacin as initial antibiotic treatment
for a lung abscess. The dosage of the drug was high (19,6
mg/kg/d), and was of necessity prolonged in view of the
nature of the pathology and the difficulty experienced in
eradicating a variety of Gram-negative pathogens. On the
44th day of therapy the patient developed a non-bullous
form of erythema multi forme, which regressed promptly
after withdrawal of the drug and the administration of
a short course of steroids. The overall clinical response
was good and the patient's progress to recovery continued
on alternative antibiotic therapy.
Patient I, a 64-year-old man in a pre-terminal state
associated with advanced lymphocytic lymphoma, was
treated with amikacin when a bronchopneumonic infection
could not be controlled with ampicillin. The clinical im-
provement observed with trial drug therapy was initially
encouraging, but Klebsiella pneumoniae was persistently
cultured from the sputum, necessitating a change to alter-
native aminoglycoside therapy with gentamicin and, sub-
sequently, tobramycin. The bacteriological response to the
latter drugs was, however, indifferent and at the time of the
patient's death 6 months later, sputum culture was still
positive for K lebsie/la.
The clinical response to the drug achieved in patient 8
was coded as poor. This elderly woman had severe chronic
obstructive airways disease complicated by bronchopneu-
monia. Enterobacter was implicated and amikacin therapy
was commenced. The patient's temperature chart showed
a swinging pyrexia which subsided after several days,
and sputum culture became negative. Antibiotic and other
supportive therapy failed to halt the progressive parenchy-
mal destruction, however, and the worsening respiratory
failure resulted in death from irreversible hypoxaemia.
Patient 4 is worthy of comment. This patient was treated
for empyema but was also receiving antituberculosis thera-
py. including streptomycin. We were reluctant to use two
aminoglycosides simultaneously. but this was thought justi-
fied in view of the patient's life-threatening Gram-negative
infection amikacin in a dosage of 17,8 mg/ kg/ d was
given.
CO CLUSIO S
Our experience. although limited, suggests that amikacin is
a valuable adjunct to current antibiotic therapy, particu-
larly in respect of Gram-negative pathogenic organisms
which are likely to prove resistant to all but aminoglycoside
treatment.
In view of the severity and refractoriness of the in-
fection in a number of cases, the dosage employed fre-
quently exceeded the manufacturer's recommendation of
15 mg/ kg/ d. Patients 8, 10, 12 and 18 in particular were
thought to deserve high dosages by virtue of their life-
threatening condition. However, the daily dose administered
fell short of the 30 mg/kg/d level which has been quoted
in the literature as consistently producing toxicity in ani-
mals treated with gentamicin and other aminoglycoside
drugs.'"
Side-effects ascribable to the use of the drug in the
present study were limited to two instances where excep-
tionally high dosages were used and were 'nonspecific'
in nature, suggestive of a hypersensitivity response. Both
were reversible, and unrelated to the nephrotoxic, ototoxic
and neuromuscular blocking effects previously documented
in respect of drugs in this group. It is concluded that ami-
kacin is an effective antibiotic which may be employed with
confidence in patients with life-threatening aerobic Gram-
negative infections, provided that there is reasonable renal
function and that the dosage does not exceed 20 mg/kg/d.
We should like to thank the BM Group (Pty) Ltd for the
supply of amikacin.
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